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Pseudomonas aeruginosa (PA) is the leading cause of corneal blindness worldwide.
A constant increase in multi-drug resistant PA strains have heightened the challenge
of effectively managing corneal infections with conventional antibiotics. Antimicrobial
peptides are promising antibiotic analogs with a unique mode of action. Cathelicidin-
derived shorter peptides (FK13 and FK16) have previously been shown to kill a range
of pathogens in both in vitro and in vivo systems. Here, our aim was to exploit the
potential of FK13 or FK16 to enhance the anti-Pseudomonas activity of vancomycin,
which normally has low clinical efficacy against PA. Our results have demonstrated that
FK16 is more potent than FK13 against different PA strains including a clinical isolate
from a patient’s ocular surface. FK16 was shown to enhance the membrane permeability
of PAO1 at sub-inhibitory concentrations. Moreover, FK16 at lower concentrations was
shown to increase the antibacterial susceptibility of vancomycin against PA strains up
to eightfold. The bactericidal synergism between FK16 and vancomycin was shown
to be stable in the presence of physiological tear salt concentration and did not cause
toxic effects on the human corneal epithelial cells and human red blood cells. Our results
have revealed that sub-inhibitory concentration of FK16 could augment the antimicrobial
effects of vancomycin against PA. It is anticipated that the future exploitation of the
peptide design approach may enhance the effectiveness of FK16 and its application as
an adjuvant to antibiotic therapy for the treatment of multi-drug resistant infections.
Keywords: Pseudomonas aeruginosa, antimicrobial peptides, vancomycin, LL-37, FK13, FK16, antibiotic
resistance, bacterial keratitis
INTRODUCTION
Pseudomonas aeruginosa is a ubiquitous Gram-negative bacterium, which causes opportunistic fatal
infections in patients with compromised immunity (e.g., HIV, burn, cancer, and cystic fibrosis)
(Poole, 2011). It is also the commonest cause of bacterial keratitis in extended-use contact lens
wearers. Pseudomonas keratitis (PsK) is a rapidly progressing disease which frequently leads to
irreversible corneal scar or melt (Hazlett, 2007). Due to its nature of the emergency, patients
are mostly hospitalized requiring aggressive treatment with mono or fortified topical drops
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formulations (Otri et al., 2013). However, fortified drops have
been shown to cause toxicity, tissue damage and reduce wound-
healing (Dua et al., 2012; Austin et al., 2017). Severe PsK cases
that require surgical transplantation of donor corneal tissue are
often at potential risk of graft tissue rejection (Rush and Rush,
2016). Moreover, constant paucity of transplant tissue and recent
emergence of multi-drug resistant (MDR) P. aeruginosa (MDRP)
has further added to the challenge to manage PsK (Willcox, 2011;
Morita et al., 2014; Vazirani et al., 2015; Tuli and Gray, 2016;
Chojnacki et al., 2019).
In developing countries such as India and Brazil, ocular
P. aeruginosa isolates have shown increased resistance to
ciprofloxacin (25 to 54%), gentamicin (10 to 46%), and
cefazolin/ceftazidime (80 to 97%) (Willcox, 2011). Moreover,
23% of cases of Pseudomonas keratitis at a single center in
India were shown to be multi-drug resistant with very poor
prognosis (Vazirani et al., 2015). In the last two decades,
developed countries in North America and Europe have also
reported an increased resistance of P. aeruginosa ocular isolates
to first-generation cephalosporins, tobramycin, polymyxin B, and
fluoroquinolones (Alexandrakis et al., 2000; Willcox, 2011; Asbell
et al., 2018). Antimicrobial resistance poses a significant impact
on public health and health services globally (Laxminarayan
et al., 2013). One of the strategic guidelines of the World Health
Organization (WHO) to combat antimicrobial resistance has
been to promote judicial use of available antibiotics both in
veterinary and hospital settings (Simonsen et al., 2004; Manyi-
Loh et al., 2018). Another strategy has been to preserve the
effectiveness of existing antimicrobials and the development of
newer alternative therapies (O’Neill, 2016; Bloom et al., 2018).
Vancomycin, a tricyclic glycopeptide discovered in the
1950s, has greater specificity toward Gram-positive bacteria
and widely used as a last resort treatment for methicillin-
resistant Staphylococcus aureus (MRSA) infection (Alvarez et al.,
2016; Yarlagadda et al., 2016b). Glycopeptide antibiotics are less
preferred as monotherapy for the management of Gram-negative
bacterial infections because of poor permeability through the
outer membrane (Yarlagadda et al., 2016a). However, once
this barrier is breached, for example with polymyxin antibiotic
(colistin), vancomycin has shown efficacy against Gram-
negative organisms. Clinical effectiveness of colistin-vancomycin
combination against MDR Gram-negative infections has been
previously demonstrated (Schina et al., 2006; Ceccarelli et al.,
2015; O’Driscoll et al., 2018). Recent reports of colistin-resistant
P. aeruginosa and potential nephrotoxicity of colistin have
discouraged their further use (Poole, 2011; Poirel et al., 2017).
This further highlights the clinical need for development and
testing of alternative approaches for effective management of
P. aeruginosa infections.
Antimicrobial peptides (AMPs) are naturally occurring
host-defense molecules with unique microbicidal properties
(Mohammed et al., 2017). These are considered to be a promising
alternative to antibiotics for the treatment of MDR bacterial
infections (Gordon et al., 2005). LL-37 is a lone member of
the cathelicidin class of AMPs that is found in humans. It has
been shown to display a broad-spectrum microbicidal activity
against a range of pathogens (Mookherjee and Hancock, 2007).
In addition, it also exhibits intracellular bactericidal and anti-
biofilm activities against a variety of Gram-negative and Gram-
positive bacteria (Wang et al., 2014; Luo et al., 2017). LL-37 is
produced by a variety of immune and non-immune mammalian
cells in response to different stimuli which subsequently aid in
immunomodulation (Rosenfeld et al., 2006). However, despite
its strong properties, the clinical use of LL-37 was limited
due to its toxicity and cost of manufacturing. Recent studies
have demonstrated that synthetic short peptides derived from
LL-37 sequence such as KR12, FK13, and FK16 are capable
of killing a variety of pathogens and do not elicit caustic
immunologic responses and host tissue toxicity (Wang et al.,
2012; Rajasekaran et al., 2017). Based on previous studies, we
aimed to test whether these peptides are capable of enhancing
the antimicrobial activity of vancomycin against different virulent
strains of P. aeruginosa and assess the safety of peptide/antibiotic
combination toward host cells.
First, we investigated the antibacterial efficacy of cathelicidin-
derived shorter peptides and antibiotics in presence of the
physiological salt concentration of tears, against a collection of
P. aeruginosa strains including a clinical isolate from a patient
with Pseudomonas keratitis. Next, we examined whether sub-
inhibitory concentrations of FK13 or FK16 would increase the
efficacy of vancomycin against P. aeruginosa. Finally, we assessed
the cytotoxic effects of peptides and the combination of peptides
and vancomycin on human corneal epithelial cells and human
red blood cells (RBCs).
MATERIALS AND METHODS
As a first step, we tested commercially synthesized peptides
[LL-37, FK13, and FK16 (200 to 0.78 µg/mL)] and antibiotics
[gentamicin (64 to 0.5 µg/mL); amikacin (16 to 0.125 µg/mL),
and vancomycin (512 to 4 µg/mL)] in broth-microdilution and
growth-inhibition assays, in presence or absence of physiological
tear salt concentration for elucidation of minimum inhibitory
concentration (MIC) and IC50 against three virulent strains of
P. aeruginosa. Bactericidal activity of FK16 was further tested by
the SYTOX-green dye uptake assay, using a known membrane-
disruptor, melittin as control. Next, the optimum concentration
of FK16 and vancomycin was tested for synergism against all
PA strains by determining fractional-inhibitory concentration
(FIC) index in the presence or absence of physiological tear
salt concentration. Gentamicin and amikacin were used as the
positive controls. Lastly, we determined the toxicity of FK16
and vancomycin alone or in combination against human corneal
epithelial cells (HCE-2) using a cell viability dye assay. The
individual methodologies are detailed below.
Bacterial Strains, Peptides, and
Antibiotics
Three P. aeruginosa strains were used in this study. PAO1-
L (Lausanne sub-line), an invasive strain, was procured
from Dr. Stephan Heeb, School of Life Sciences, University
of Nottingham, United Kingdom. P. aeruginosa ATCC
19660, which is cytotoxic, was obtained commercially from
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ATCC-LGC Standards, United Kingdom. A clinical isolate of
P. aeruginosa (PA-OS) from scrapes of human corneal surface
with severe corneal melt was obtained from the Department
of Clinical Microbiology, Nottingham University Hospitals,
United Kingdom. All the work in this study was conducted
as per the Health and Safety laboratory guidelines under the
Biological safety standards of the University of Nottingham.
Cation-adjusted Mueller-Hinton broth (MHB-II), Mueller-
Hinton agar (MHA), and Tryptic soy agar (TSA) were purchased
from Sigma-Aldrich, United Kingdom. P. aeruginosa selective
agar F was procured from Merck Millipore, United Kingdom.
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES),
FK13 (FKRIVQRIKDFLR) and FK16 (FKRIVQRIKDFLRNLV)
were purchased from Anaspec, Fremont, CA, United States.
Gentamicin and Amikacin were commercially obtained from
Sigma-Aldrich, United Kingdom. Vancomycin Hydrochloride
was procured from MP Biomedicals, France.
Broth Microdilution Assay
Minimum inhibitory concentration was determined for peptides
and antibiotics in duplicate using broth microdilution assay
according to CLSI guidelines (Wiegand et al., 2008). Twofold
serial dilution of peptides and antibiotics were made in duplicate
across the 96-well polypropylene microtiter plate using acidified
water (0.01% Acetic acid and 0.1% Bovine serum albumin). This
resulted in 10 µL of 10x concentration of peptides or antibiotics
(gentamicin, amikacin, and vancomycin) in each well. Three to
five colonies of PA strain from MHA culture plate were incubated
in 5 mL MHB-II in an orbital shaker at 35◦C for 16 h. The
overnight cultures were sub-inoculated in fresh 5 mL MHB-II
at 1 in 50 dilutions and incubated for 3–4 h in the shaking
incubator at 35◦C until OD600 readings gave approximately
2 × 108 CFU/mL. A suspension of 1 × 106 CFU/mL in fresh
MHB-II was prepared by further dilution and 90 uL of this
suspension was then transferred to each well-containing 10 uL
of 10x peptide or antibiotics which resulted in final inoculum
of 5 × 105 CFU/mL with desired final concentration of peptide
(range 200 to 0.78 µg/mL) or antibiotics [gentamicin (64 to
0.5µg/mL); amikacin (16 to 0.125µg/mL), and vancomycin (512
to 4µg/mL)]. Growth control (only bacteria) and sterility control
(no bacteria) were also included in each plate. The plate was
incubated at 37◦C for 18–21 h and the MIC was determined as
the lowest concentration of peptide or antibiotic that inhibited
the visible growth of PA strain as observed with the unaided eye.
Growth Inhibition Assay
Three to five colonies of a PA strain were incubated overnight
in 5 mL MHB-II at 35◦C in an orbital shaker. The overnight
bacterial culture was then diluted to 1 in 50 in fresh MHB-II
(5 mL) and further incubated for 3–4 h at 35◦C in an orbital
shaker to achieve 0.3 OD600 (approximately 2 × 108 CFU/mL).
Twofold serial dilution of each peptide or antibiotic (gentamicin,
amikacin, and vancomycin) in duplicate at 2x concentration
in 100 µL was prepared in acidified water containing 0.002%
polysorbate-80 (to prevent binding of cationic peptides to the
anionic surface of the plate) in a 96-well microtiter polystyrene
plate. To each well, 100 µL of bacterial suspension containing
1 × 106 bacteria/mL in MHB-II/0.002% polysorbate-80 was
added, which resulted in the inoculum of 5 × 105 CFU/mL
per well in 200 µL final volume. In addition, individual wells
containing vehicle control (1% DMSO) and positive control
(50 µg/mL melittin) was also prepared. The plate was incubated
at 37◦C for 21 h in BMG Clariostar microplate reader and
OD600 measurements were recorded at 30 min intervals. Two
independent experiments were performed for each peptide
and antibiotic. Percent growth of bacteria at 13 h for each
concentration of peptide and antibiotic was estimated. The IC50
value (concentration at which growth reduced to 50%) was then
derived from non-linear regression curves using the GraphPad
Prism (version 8.0). Growth inhibition assay was also performed
for different concentrations of vancomycin (512 to 0 µg/mL,
twofold decreasing serial dilutions) against all the three PA
strains alone or in combination with FK16 peptide at 0.5x MIC
(50 µg/mL) and 0.25x MIC (25 µg/mL), respectively.
Time-Kill Assay
An overnight culture, each of PAO1-L and PA19660
(approximately 16–18 h) was diluted 50-fold (1 in 50) in
fresh MHB-II and further incubated at 35◦C in an orbital shaker
for 3–4 h until 0.3 OD600 (approximately 2 × 108 CFU/mL)
was achieved. PAO1-L suspension (2 × 106 CFU/mL) was
incubated with FK16 peptide (2 or 0.5x MIC) with or without
vancomycin (128 or 256 µg/mL) at 35◦C in an orbital shaker. At
0 (starting), 0.5, 3, and 24 h time-points, 10µL of the mixture was
aliquoted and serially diluted in sterile 1x phosphate-buffered
saline (PBS), pH 7.2. The diluted bacteria were spread on MHA
plates in duplicate and incubated at 37◦C for 24 h. Colony
count (CFU/mL) was performed and the concentration of
FK16 or vancomycin (alone or in combination) was considered
bactericidal if there was a ≥ 3 log10 reduction in CFU/mL.
SYTOX-Green Dye Uptake Assay
SYTOX-green does not permeate viable bacteria, but once inside
the cytoplasm it binds the nucleic acids and emit fluorescence
(λEX = 488 nm; λEM = 520 nm). PAO1 and PA19660 were
grown overnight in MHB-II medium and further sub-cultured
to a mid-logarithmic growth phase (up to 3 h) at 35◦C in an
orbital shaker. The suspension was spun at 3000 rpm for 10 min,
washed with PBS and diluted to 0.05 OD600 in 10% MHB2. To
the diluted bacteria, SYTOX-green dye at a final concentration
of 2 µM was added and incubated for 15 min. A 96-well black
propylene plate containing a mix of 100 µL of bacteria-SYTOX
green suspension and 100 µL of FK16 (at 2x concentrations) or
melittin (20 µg/mL; positive control) or PBS (negative control)
in each well was placed in a fluorescence plate reader (BMG
Clariostar) for 30 min. The relative fluorescence unit (RFU) was
analyzed by deducting fluorescence from PBS treated bacteria.
Two independent experiments were performed in duplicates
for each strain.
Checkerboard Assay
The combined activity and interactions (synergism, sum of
activities, or antagonism) between peptides and vancomycin
against PA strains in presence or absence of 150 mM
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NaCl (physiological salt concentration) was determined using
checkerboard assay method (7 × 7 matrix format). 25 µL of
test peptide at 4x concentration was serially diluted (twofold) in
decreasing concentration (final 160 to 0 µg/mL) from column 2
to 8 of a 96-well microtiter polypropylene plate (labeled as ‘Main
plate’). In another 96-well plate (labeled as ‘Helper plate’), 25 µL
of vancomycin at 4x concentration was prepared in twofold step
dilutions (final 512 to 0 µg/mL) from row B to H. The contents
from each well of the helper plate was then transferred to the
corresponding wells of the main plate to set up an equal 1:1 mix of
peptide and vancomycin. The bacterial suspension was prepared
(as described in above sections) and diluted to 1 × 106 CFU/mL
in fresh MHB-II. 50 µL of diluted suspension (containing 0
or 300 mM NaCl) was then added to each well, resulting in
final inoculum of 5 × 105 CFU/mL in 100 µL total volume
(final 0 or 150 mM NaCl). Positive control (melittin 50 µg/mL),
vehicle control (1% DMSO), and sterility control (no bacteria)
was also included in all assay plates. After 21 h of incubation
at 37◦C, the plates were visually examined for growth. The
FIC index for combination of each peptide and vancomycin (in
MHB-II ± 150 mM NaCl) against each PA strain was calculated
as [(MIC of peptide in combination with vancomycin)/(MIC
of peptide alone)] + [(MIC of vancomycin in combination
with peptide)/(MIC of vancomycin alone)]. The results were
interpreted as FIC ≤ 0.5, synergistic; 0.5 < FIC ≤ 1, additive;
1< FIC ≤ 4, indifferent; FIC> 4, antagonistic (Ng et al., 2018).
Cytotoxicity Assay
Human corneal epithelial cells (HCE-2, ATCC) were cultured
in keratinocyte serum-free media (KSFM) supplemented with
human recombinant epidermal growth factor and bovine
pituitary extract. HCE-2 cells were seeded into a 96-well plate
at a density of 7.5 × 103 cells per well and allowed to attach
overnight. After 24 h of treatment with different concentration of
peptides and vancomycin (alone or in combination) in duplicate,
the viability of cells was measured using CCK-8 assay kit (Sigma,
United Kingdom) as per manufacturer’s guidelines. The WST-
8 reagent was bio-reduced by the viable cells into a colored
formazan product, which was measured at OD450 using BMG
Clariostar microplate reader. Percent viable cells was calculated
as [(OD450 of cells treated with peptide or antibiotic)/(OD450 of
untreated cells)] x 100.
Hemolysis Assay
Human blood for hemolysis assay was collected from the healthy
subjects with prior consent under the approved ethics (Reference
No. 176-1812) from the local Research Ethics Committee of
the Faculty of Medicine and Health Sciences, University of
Nottingham. Blood was collected in EDTA-coated tube and
centrifuged for 10 min at 1300 × g for separation of plasma.
RBCs were rinsed three times in Ca2+/Mg2+ free PBS by
centrifugation for 5 min at 1300 g. RBCs were diluted to 4%
vol/vol in PBS and incubated with 100 µL of LL-37 and FK16
(200 to 0.78 µg/mL), vancomycin alone (512 to 2 µg/mL)
and in combination with FK16 (50 µg/mL), 1% Triton X-100
(positive control) and PBS (negative control) for 1 h at 37◦C
in a U-bottom polypropylene 96-well plate. The plate was then
centrifuged at 1300 × g for 10 min and 100 µL of supernatant
was transferred into 96-well polystyrene plate. The absorbance
was measured at 540 nm for estimation of percentage hemolysis
compared to the positive control. Percent lysis was calculated
as [(OD540 of suspension from RBC treated with peptide and
antibiotic alone or in combination – OD540 of suspension from
negative control-treated RBCs)/(OD540 of suspension treated
with positive control – OD540 of suspension from negative
control-treated RBCs)] x 100.
RESULTS
Anti-Pseudomonas Activity of Peptides
and Antibiotics
LL-37 and its two derivatives, FK13 and FK16, and a range
of antibiotics that are commonly used for the treatment of
bacterial keratitis were tested against three different strains of
Pseudomonas aeruginosa (PAO1, PA19660, and PA-OS). The
biochemical and structural details of peptides and antibiotics
was depicted in the Supplementary Table 1. As shown in
Table 1, LL-37 demonstrated higher bactericidal activity against
all PA strains when compared to FK16 (50 vs. 100 µg/mL)
and FK13 (50 vs. 200 µg/mL), respectively. Of the two
shorter peptides, FK16 showed stable bactericidal activity
against PAO1, PA19660, and PA-OS. All antibiotics, except
vancomycin (>256 µg/mL), showed potent anti-Pseudomonas
activity. Amikacin, in particular, demonstrated a fourfold higher
bactericidal activity compared to gentamicin. However, in the
presence of physiological salt concentration (150 mM NaCl), the
MIC of gentamicin, amikacin, LL-37, and FK16 was reduced
twofold against all tested strains. FK13 was shown to be
ineffective at the highest test concentration (200 µg/mL) in the
presence of salt against PA19660 and PA-OS indicating that there
was no difference in the behavior of FK13 and FK16 with respect
to reduction of activity in the presence of salt.
As an alternative dynamic methodology to static MIC
(Ng et al., 2018), the efficacy of FK16 and FK13 against all
PA strains was tested using kinetic growth-inhibition assay.
The sigmoidal dose-response curves for FK16 (Figure 1A)
showed sharp decrease in percentage growth of PAO1
(IC50 = 21.3 ± 3.5 µg/mL), PA19660 (IC50 = 29 ± 4.2 µg/mL)
and PA-OS (IC50 = 27 ± 3.2 µg/mL). In contrast, FK13
(Figure 1B) showed > 2-fold reduced activity compared to
FK16 in inhibiting PAO1 (IC50 = 49.3 ± 4.2 µg/mL), PA19660
(IC50 = 89.5 ± 6 µg/mL), and PA-OS (IC50 = 91.5 ± 8 µg/mL).
Against PAO1, LL-37 (IC50 = 16.3 ± 6.2 µg/mL), gentamicin
(IC50 = 3 ± 1.5 µg/mL), and amikacin (IC50 = 0.5 ± 0.1 µg/mL)
all showed higher killing activity (Supplementary Figure 1
and Supplementary Table 2). However, vancomycin
required a higher concentration to inhibit PAO1 growth
(IC50 > 291 µg/mL).
GF-17 (also known as N-glycinated FK16) has been previously
shown to kill Escherichia coli via membrane-disruption (Wang
et al., 2017). To validate whether the FK16 also kills P. aeruginosa
utilizing a similar mechanism, we performed the SYTOX-
green dye uptake assay. The increased intensity of fluorescence
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TABLE 1 | Minimum inhibition concentration (MIC) of the antimicrobial peptides
and antibiotics against three different Pseudomonas aeruginosa strains.
µg mL−1 (µM) PAO1a PA 19660b PA-OSc
NaCl
0 mM 150 mM 0 mM 150 mM 0 mM 150 mM
LL-37 50
(11.12)
100
(22.24)
50
(11.12)
100
(22.24)
50
(11.12)
100
(22.24)
FK13 100
(28.14)
200
(116.28)
200
(116.28)
>200
(>116.28)
200
(116.28)
>200
(>116.28)
FK16 100
(48.85)
200
(97.70)
100
(48.85)
200
(97.70)
100
(48.85)
200
(97.70)
Gentamicin 4
(8.37)
8
(16.74)
4
(8.37)
8
(16.74)
4
(8.37)
8
(16.74)
Amikacin 1
(1.71)
2
(3.42)
1
(1.71)
2
(3.42)
1
(1.71)
2
(3.42)
Vancomycin >256
(>176)
>256
(>176)
>256
(>176)
>256
(>176)
>256
(>176)
>256
(>176)
aOpportunistic pathogen that causes invasive infection. bCytotoxic
strain from ATCC. cClinical isolate from the ocular surface of patient.
corresponds to the membrane disruption and binding of the
dye to the nucleic acids of the bacterium. As shown in
Figure 2A, the influx of SYTOX-green dye in PAO1 was directly
proportional to the concentration of FK16 and the maximum
relative fluorescence was noted at 1x MIC. Melittin, a known
membrane disruptor from honey-bee venom, was used as a
positive control. We further assessed the killing efficacy of FK16
(1, 0.5, and 0.25x MIC) against PAO1 at 5-min interval up to
30 min and then at 60 min and 24 h, respectively. As shown in
Figure 2B, FK16 at 1x MIC was shown to kill PAO1 at 60 min
with no growth noted up to 24 h. Whilst LL-37 at 1x MIC was
shown to kill PAO1 at 30 min.
Antimicrobial Effect of Peptides and
Vancomycin Combination Against
P. aeruginosa
As demonstrated above, vancomycin failed to exhibit significant
bactericidal activity against P. aeruginosa (MIC > 256 and
IC50 > 291 µg/mL). This is due to poor permeation of
vancomycin through the outer membrane of P. aeruginosa. Based
on the ability of FK16 to modulate membrane permeability, we
hypothesized that in combination with FK16 the antimicrobial
susceptibility of vancomycin against P. aeruginosa could be
augmented. To test this hypothesis, we performed the growth-
inhibition assay for the combination of FK16 (at sub-MIC levels;
25 and 50 µg/mL) and vancomycin (512 to 0 µg/mL in twofold
serial dilution) against all three PA strains. Kinetic kill curves
(Supplementary Figure 2) were plotted using OD600 readings
that were recorded at 30 min intervals up to 21 h. The normalized
percentage growth of each strain at 13- and 21-h time point was
then calculated for analysis of FK16 + vancomycin combination
against P. aeruginosa.
As shown in Figure 3 (orange bars), at 21-h time point,
FK16 (25 µg/mL) enhanced the killing efficacy of vancomycin
FIGURE 1 | Dose response curves of FK16 (A) and FK13 (B) against PAO1,
PA19660, and PA-OS. Percentage growth is presented as mean ± standard
deviation (SD) of two independent experiments performed in triplicate (n = 6
data sets). The IC50 values were depicted in the Table 2. Some of the error
bars are missing due to smaller SD.
by eightfold (512 vs. 64 µg/mL) against PAO1 (Figure 3D),
PA-19660 (Figure 3E), and PA-OS (Figure 3F). Moreover, at
25 µg/mL FK16 + 64 µg/mL vancomycin combination, >99.5%
normalized growth of PAO1 (Figure 3D) and >95% of both
PA19660 (Figure 3E) and PA-OS (Figure 3F) were shown
to be inhibited. To assess whether the bactericidal activity of
vancomycin is dependent on FK16 concentration, we increased
the concentration of FK16 to 50 µg/mL (0.5x MIC) in the growth
TABLE 2 | IC50 values derived from the dose-response curves for FK13 and FK16.
FK13 FK16
∗ IC50 (µg
mL−1)
Standard
deviation
R2 ∗ IC50 (µg
mL−1)
Standard
deviation
R2
PAO1 49.3 2.2 0.965 21.3 3.5 0.990
PA-19660 89.5 6.1 0.814 29 4.1 0.993
PA-OS 91.5 8.1 0.881 27 3.2 0.979
∗ IC50, concentration at which 50% of the bacterial growth was inhibited.
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FIGURE 2 | Killing mechanism of FK16 against PAO1. (A) Fluorometric analysis of SYTOX-green dye uptake in PAO1. Fluorescence emission was recorded at
λ = 520 nm at 5 min interval up to 30 min. Relative fluorescence unit (RFU) vs. time plots for different concentrations of FK16 (in µg/mL), Melittin (20 µg/mL), or PBS
control (untreated) were constructed. Data representing three independent experiments performed in duplicate. (B) Killing kinetics of PAO1. Bacteria were treated
with vehicle (closed circle), FK16 at 1x MIC (open diamond), 0.5x MIC (open triangle) and 0.25x MIC (open square) and LL-37 at 1x MIC (open circle) for 5, 10, 15,
20, 25, 30, 60, and 1440 min, respectively. ‘0 h’ represents the starting inoculum. Colonies were counted (CFU/mL) 24 h post-treatment from serial dilutions in
duplicate and presented in a logarithmic scale. Data is presented as mean ± standard deviation (SD) of three independent experiments. Some of the error bars are
missing due to smaller SD.
inhibition assay. We have noted an 16-fold improvement in
bactericidal activity against PAO1 [512 vs. 32µg/mL; (Figure 3D,
cyan bars)] and eightfold improvement against PA19660 and
PA-OS (512 vs. 64 µg/mL; Figures 3E,F, cyan bars), respectively.
We further validated the killing kinetics of FK16-vancomycin
combination against PAO1 and PA19660 in a time-kill assay.
Gentamicin, which was used as a positive control (5x MIC;
20µg/mL) and FK16 at twofold above the MIC (200µg/mL) have
been shown to completely kill PAO1 (Figure 4A) and PA19660
(Figure 4B) at 45 min. Notably, FK16 (50 µg/mL; sub-MIC) in
combination with vancomycin (128 µg/mL) have been shown
to completely inhibit the growth of both strains at 2 h and
demonstrated sustained activity up to 24 h. With combination
of FK16 (50 µg/mL; sub-MIC) and vancomycin (256 µg/mL;
twofold higher concentration), PAO1 (Figure 4A) and PA19660
(Figure 4B) were shown to be reduced > 3 log10(CFU/mL)
within 60 min and complete kill achieved by 2 h with no growth
noted up to 24 h.
To establish a synergistic or additive effect of the FK16
and vancomycin combination, a MIC-based checkerboard assay
against all three PA strains was performed. In addition, we have
also examined the combination effect in the presence of 150 mM
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FIGURE 3 | Normalized percentage growth of PAO1 (A,D), PA-19660 (B,E), and PA-OS (C,F) from OD600 recordings at 13-h (early stationary phase) and 21-h (late
stationary phase) time point following treatment with FK16 and vancomycin combination. Vancomycin (VCN) alone treatment (512 to 0 µg/mL) is represented with
black bars. VCN (512 to 0 µg/mL) + FK16 at 25 µg/mL (orange bars) and VCN (512 to 0 µg/mL) + FK16 at 50 µg/mL (cyan bars). Vehicle treatment (clear bar) and
FK16 alone at 25 µg/mL (red bar) and 50 µg/mL (blue bar). Data is presented as mean ± standard deviation (SD) of two independent experiments performed in
triplicate (n = 6 data sets). Some of the error bars are missing due to smaller SD. Inhibition is seen up to the 21-h time point (D–F).
NaCl. As depicted in Table 3, FK16-vancomycin combination
has demonstrated synergistic bactericidal activity against PAO1
(FICI = 0.25), PA19660 (FICI = 0.375), and PA-OS (FICI = 0.375),
respectively. In the presence of physiological salt, combination
of FK16 and vancomycin remained synergistic against PAO1
(FICI = 0.375). Although the combination effect against PA19660
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FIGURE 4 | Time-kill curves of FK16 and vancomycin alone or in combination against PAO1 (A) and PA19660 (B). Bacteria were treated with FK16 alone (2x MIC;
open magenta triangle) and (0.5x MIC; open orange diamond), VCN alone (256 µg/mL; closed black circle), FK16 (0.5x MIC) + vancomycin (VCN; 128 µg/mL closed
brown square), FK16 (0.5x MIC) + VCN (256 µg/mL; closed green triangle), Gentamicin (5x MIC; open blue square) and vehicle (open red circle) for 15, 30, 45, 60,
120, 180 and 1440 min, respectively. ‘0 minutes’ represents the starting inoculum. Colonies were counted (CFU/mL) 24 h post-treatment from serial dilutions in
duplicate and presented in a logarithmic scale. Data is presented as mean ± standard deviation (SD) of three independent experiments. Some of the error bars are
missing due to smaller SD.
(FICI = 0.50) and PA-OS (FICI = 0.50) have been slightly
reduced in assay buffer containing 150 mM NaCl, the FIC indices
against both strains were still at the borderline between synergism
and additive level.
Potential Toxicity of Peptides and
Vancomycin Toward Human Corneal
Epithelial Cells and Human Red Blood
Cells
Antimicrobial peptides at higher concentrations have been shown
to elicit toxic responses on host tissue. This non-selective
effect of AMPs has therefore limited their clinical application
(Haney et al., 2019). Here, we evaluated the potential cytotoxic
effects of cationic peptides (LL-37, FK13, and FK16), vancomycin
and different concentrations of FK16 in combination with
vancomycin on human corneal epithelial cells (HCE-2, ATCC)
until 24 h treatment duration. As shown in Figure 5A, LL-
37 has demonstrated significant cytotoxic effects on HCE2
(EC50 = 43.20 ± 4.08 µg/mL). Notably, EC50 value of LL37
was matching to its 1x MIC levels against P. aeruginosa
(Table 1). FK13 and FK16 were shown to be non-toxic to HCE2
(EC50 > 200 µg/mL; Table 4). Similarly, treatment of HCE2 for
24 h with different concentrations of vancomycin either alone
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TABLE 3 | Effect of FK16 and Vancomycin combination in presence and absence
of physiological salt concentration.
FK16 + VCN 0 mM NaCl 150 mM NaCl
FIC index Interpretationa FIC index Interpretationa
PAO1 0.25 Synergy 0.375 Synergy
PA-19660 0.375 Synergy 0.50 Synergy
PA-OS 0.375 Synergy 0.50 Synergy
aFIC Index = (MIC FK16 comb/MIC FK16 alone) + (MIC VCN comb/MIC VCN alone).
FIC ≤ 0.5 represents synergy. FIC between 0.5 and 2 represents additive effect.
FIC ≥ 2 represents inhibitory effect.
FIGURE 5 | Toxic effects of peptides (A) and vancomycin (VCN) + FK16
combination (B) against human corneal epithelial cells (HCE-2). After 24 h of
treatment with different concentration of peptides alone or in combination with
different concentration of VCN, HCE2 viability was assessed with CCK8
reagent. EC50 and Vmax was derived (Table 4) from the percentage viable cell
curves using GraphPad Prism (ver. 8.0). Data is presented as
mean ± standard deviation (SD) of three independent experiments performed
in duplicate. Some of the error bars are missing due to smaller SD.
(EC50 > 512 µg/mL) or in combination with FK16 at 25 µg/mL
(EC50 > 512 µg/mL) or 50 µg/mL (EC50 > 512 µg/mL) have not
elicited toxic effects (Figure 5B).
We also assessed the hemolytic effect of peptides and
vancomycin alone or in combination on human red blood cells
(hRBC). LL-37 displayed 25.03 ± 1.97 percent lysis of hRBC at
256 µg/mL (Figure 6). Whereas FK16 exhibited 13.61 ± 3.29%
lysis at 256 µg/mL. Vancomycin alone (512 to 2 µg/mL)
or in combination with FK16 (50 µg/mL) did not induce
significant hemolysis.
TABLE 4 | Toxic effects of peptides and vancomycin against HCE-2 cells.
aEC50 µg mL−1 (SD) bVmax % (SD)
LL-37 43.20 (4.08) 15.08 (5.76)
FK13 >200 69.49 (3.36)
FK16 >200 58.75 (4.54)
VCN >512 79.67 (8.15)
VCN + FK16 (25 µg mL−1) >512 70.21 (2.08)
VCN + FK16 (50 µg mL−1) >512 69.18 (3.09)
aEC50 – Concentration at which 50% of the cell viability was reduced. bVmax
– Percentage (%) cell viability at the highest concentration of peptides and
vancomycin (all peptides = 200 µg mL−1 and vancomycin = 512 µg mL−1).
DISCUSSION
The growing threat of MDR P. aeruginosa has profoundly affected
a diverse patient cohort and health services worldwide. A key
strategy to counter the antimicrobial resistance would be to
exploit the potential of AMPs to improve the effectiveness of
conventional antibiotics (Hollmann et al., 2018). This approach
was deemed unique because of the differences in the mechanisms
of action of AMPs compared to antibiotics.
In the present work, we have selected LL-37 and its shorter
peptides on the basis of previous findings from our and another
laboratories (McIntosh et al., 2005; Huang et al., 2006, 2007;
Wang et al., 2012, 2014; Rajasekaran et al., 2017). LL-37 was
shown to be abundantly expressed on the human ocular surface
in response to P. aeruginosa (McIntosh et al., 2005; Huang et al.,
2006). Moreover, its genetic deletion in mouse has been shown
to increase the susceptibility to Pseudomonas keratitis (Huang
et al., 2007). Thus, there is sufficient evidence in the literature to
justify a study to explore the efficacy and safety of AMPs or AMP-
derived peptides in isolation and in combination with antibiotics.
Published results from the Steroids for Corneal Ulcers Trial
(SCUT) have shown that the corneal ulcers with genotypically
invasive P. aeruginosa subgroup have marked differences in
the clinical presentation and responses to treatment when
compared to genotypically cytotoxic P. aeruginosa subgroup
(Borkar et al., 2013). A subsequent report from the SCUT
study has further demonstrated that exoU(+) encoding cytotoxic
P. aeruginosa isolates were significantly resistant to ciprofloxacin,
gatifloxacin, and ofloxacin compared to exoU(−) P. aeruginosa
strain (Borkar et al., 2014). This illustrates that the specific
virulence determinants of a single species of a pathogen respond
differently to treatment. Although LL-37 was found to be twofold
more potent than its shorter peptides against P. aeruginosa, its
detrimental effect on corneal epithelial cells made it undesirable
for further synergism experiments in the context of ocular surface
infections. Our results agree with earlier studies which also
demonstrated the toxicity of LL-37 against RBCs and a variety
of human cell lines (Jaskiewicz et al., 2018; Haney et al., 2019).
Structure-activity relationship (SAR) studies have enabled
the development of short fragments of LL-37 with improved
cell selectivity (Mookherjee and Hancock, 2007; Mishra et al.,
2013; Wang et al., 2014). It was shown that the region
between 2 and 31 residues of LL-37 is important for
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FIGURE 6 | Lytic effect against human red blood cells (RBCs). After 1 h of treatment with different concentration of LL-37 (closed circle; 200 to 0 µg/mL), FK16
alone (closed square; 200 to 0 µg/mL), VCN alone (upright open triangle; 512 to 8 µg/mL) and in combination with FK16 at 50 µg/mL (inverted open triangle),
hemolysis was assessed by measuring optical absorbance of supernatant at 540 nm. Percentage lysis curves were plotted using GraphPad Prism (ver. 8.0). Data is
presented as mean ± standard deviation (SD) of three independent experiments performed in duplicate. Some of the error bars are missing due to smaller SD.
antibacterial activity (Li et al., 2006). A recent study utilizing
nuclear magnetic resonance (NMR) has confirmed that the
amino acid residues between 17 and 32 (i.e., FK16) have
strong binding affinity toward anionic (bacterial) but not
zwitterionic (host) model membranes (Wang et al., 2012).
Moreover, FK16 has been shown to exhibit strong bactericidal
activity against ESKAPE organisms (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumanii, Pseudomonas aeruginosa, and Enterobacter spp.)
(Mishra and Wang, 2017). GF17, a N-glycinated variant of FK16,
has also been shown to exhibit anti-cancer (Ren et al., 2013),
anti-bacterial (Wang et al., 2012; Kiattiburut et al., 2018) and
anti-viral activities (He et al., 2018). It was further confirmed
that GF17 and its structurally modified variants were able to
kill a variety of Gram-negative and Gram-positive bacteria via
membrane disruption (Wang et al., 2017). In addition, GF17 and
17BIPHE2 (second generation peptide based on GF17 structure)
precoated biomaterials were shown to prevent bacterial biofilm
formation both in in vitro and in vivo model systems (Mishra
and Wang, 2017). Consistent with the above reports, we have also
demonstrated that FK16 is more effective than FK13 against all
P. aeruginosa strains and specifically damages the cell membranes
as confirmed with the SYTOX-green uptake assay. However,
the activity of FK16 was found to be slightly reduced in the
presence of physiological salt conditions. A similar observation
has been reported with GF17 activity against E. coli (Wang et al.,
2017), which suggested that the rate of interaction between the
peptide and bacterial membrane may reduce under physiological
salt conditions.
Although antibiotics have been shown in this study to kill
P. aeruginosa at lower concentrations than LL-37 and its smaller
peptides, they are clinically used at very high concentration, i.e.,
between 0.3 and 1.5% as topical formulations (3 mg/mL; used
at > 1500x MIC) for the treatment of Pseudomonas keratitis
(Dua et al., 2012; Otri et al., 2013). AMPs, on the other hand,
have been shown to exhibit in vivo bactericidal efficacy at low
micromolar concentrations (Gordon et al., 2005; Beaumont et al.,
2014; Kolar et al., 2015; Pletzer et al., 2017; Wuerth et al., 2019).
Given the low antimicrobial efficacy of the small peptides, which
is compounded by the tear salt concentration and presence of
other proteases, a 4x MIC concentration (800 µM) would be
needed for therapeutic effect. This would be too high but in
combination with antibiotics, the former can be used in sub-
inhibitory concentrations thus minimizing their cytotoxic effects
whilst potentiating the effect of the antibiotics to effectively treat
ocular surface infections.
The standard MIC assay is useful for ascertaining the
antibacterial efficacy of a test compound at the end of a fixed
time-point (18 or 21 h). However, it does not provide detailed
information on the growth-rate inhibition of bacteria in response
to different concentrations of an antimicrobial agent (Abdelbaqi
et al., 2016; Ng et al., 2018). Here, we further validated the
antimicrobial activity of our peptides and antibiotics utilizing
a dynamic pharmacological approach for the generation of
dose-response curves. The resultant growth inhibition curves
from OD600 measurements have allowed us to report the IC50
readings (concentration at which 50% of the bacterial growth was
inhibited) in addition to MIC values for all our test compounds.
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In our experiments ‘growth inhibition’ could be a reflection of
the initial kill of the bacteria by the agents used rather than
retardation of growth (of the surviving bacteria) as would be
seen by alteration of pH for example. However, the use of
term ‘inhibition’ here would be in the same context as used in
MIC assay where the ‘growth inhibition’ is a reflection of the
killing of bacteria.
We have noted that the activity of FK13 but not FK16 was
greatly reduced against cytotoxic PA19660 and ocular PA isolate.
Although not tested here, it is likely that FK13 may require
higher concentration (>200 µg/mL) to achieve similar efficacy as
FK16 against P. aeruginosa in the presence of salt. Moreover, the
enhanced activity of FK16 could be attributed to the additional
hydrophobic residues on the C-terminus (Leu31 and Val32 as
per LL-37 sequence). Interestingly, a previous structural study
has provided evidence that C-terminus residues of FK16 were
shown to form a 310 helix (Li et al., 2006). However, implication
of these hydrophobic residues to the functional activity of FK16
against Gram-negative strains of different virulence was not
well-understood. Our comparison of FK13 and FK16 activity
have revealed that the hydrophobic C-terminus of FK16 is
key for stable bactericidal activity against cytotoxic and ocular
P. aeruginosa strains. It is anticipated that further SAR studies
would validate our findings and may lead to the development of
rationally designed analogs of FK16.
The results from our study are in agreement with earlier
reports that vancomycin exhibits much weaker activity against
P. aeruginosa (Alvarez et al., 2016; Ng et al., 2018; Pletzer et al.,
2018). Earlier studies have demonstrated that polymyxins and
ciprofloxacin are capable of enhancing the activity of vancomycin
against P. aeruginosa (Day et al., 1993; Ng et al., 2018). However,
the wider use of antibiotic combinations has been greatly
discouraged due to the increased risk of toxicity (Poole, 2011; Dua
et al., 2012; Vazirani et al., 2015).
Synergism between antibiotics and AMPs has been
demonstrated both in in vitro and in vivo infection model
systems (Blazewicz et al., 2018; Pletzer et al., 2018). Synthetic
AMPs such as 1008 and DJK-5 were shown to kill P. aeruginosa
via disruption of stringent-stress response pathway (Pletzer et al.,
2017). It was further demonstrated that the cutaneous abscesses
caused by ESKAPE pathogens can be successfully treated with the
combination of peptides and conventional antibiotics (Pletzer
et al., 2018). A modified FK13 peptide, FK13-a1, was also shown
to enhance the activity of chloramphenicol against MDR bacteria
both in the presence and absence of salt (Rajasekaran et al., 2017).
Our results have demonstrated that FK16 at sub-MIC levels
was capable of enhancing the susceptibility of P. aeruginosa
against vancomycin (up to eightfold). Moreover, further analysis
in checkerboard assays has shown that FK16 activity in
combination with vancomycin is stable in the physiological tear
salt conditions. Although MIC-based checkerboard assay has
its own limitation, our results from plate-count experiments
implicated a possible synergism between FK16 and vancomycin
against both invasive and cytotoxic strain of PA. Thus, while
further assessment of FK16-vancomycin in in vivo bacterial
keratitis model is required, it may be reasonable to infer that
the observed synergism/additive effect would likely be effective
in the treatment of P. aeruginosa that have already demonstrated
multi-drug resistance. The exact mechanism of the enhanced
effect of the two agents together is unclear. Though increased
permeabilization of the membrane(s) is observed with FK16,
it does not directly suggest the mechanism by which the
enhanced effect is achieved. Despite meticulous attention to
details regarding time of incubation, volume and concentration
of inoculum, subtle errors can inadvertently creep in and
affect the outcome and consequent FIC index. Thus, though
suggestive of synergism, it is not conclusive. To bring this
one step closer to the therapeutic realization, we have also
shown that FK16 + vancomycin combination is non-toxic to
the human corneal epithelial cells and human RBCs. Therefore,
our in vitro results have the potential to form the basis
for early preclinical studies particularly for the assessment of
toxicity and pharmacokinetic properties of combination therapy
including compatibility of formulation, stability, and effective
administration route.
In summary, FK16 alone or in combination with vancomycin
has shown enhanced ability to kill P. aeruginosa of different
virulence without eliciting host cell toxicity. These results provide
further credence to the overarching concept of developing the
next generation of AMP-antibiotic combination therapies as a
viable option to counter antibiotic resistance. Future studies
to test the preclinical efficacy of FK16-vancomycin synergism
against PA in an in vivo model of bacterial keratitis are planned
to take this concept further toward clinical realization.
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